Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).
Piccirillo MC, Chu Q, Bradbury P, Tu W, Coschi CH, Grosso F, Florescu M, Mencoboni M, Goffin JR, Pagano M, Ciardiello F, Cecere FL, Vincent M, Ferrara R, Dawe DE, Hao D, Lee CW, Morabito A, Gridelli C, Cavanna L, Iqbal M, Blais N, Leighl NB, Wheatley-Price P, Tsao MS, Ugo F, El-Osta H, Gargiulo P, Gaudreau PO, Tu D, Sederias J, Brown-Walker P, Perrone F, Seymour L, Laurie SA. Piccirillo MC, et al. Among authors: laurie sa. J Thorac Oncol. 2023 Jun;18(6):813-819. doi: 10.1016/j.jtho.2023.02.003. Epub 2023 Feb 24. J Thorac Oncol. 2023. PMID: 36841541 Clinical Trial.
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, Goss G, Powers J, Walsh W, Tu D, Robertson J, Puchalski TA, Seymour L. Laurie SA, et al. J Clin Oncol. 2008 Apr 10;26(11):1871-8. doi: 10.1200/JCO.2007.14.4741. J Clin Oncol. 2008. PMID: 18398152 Clinical Trial.
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.
Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, Feld R, Powers J, Seymour L. Goss G, et al. Eur J Cancer. 2009 Mar;45(5):782-8. doi: 10.1016/j.ejca.2008.10.022. Epub 2008 Dec 16. Eur J Cancer. 2009. PMID: 19091548 Clinical Trial.
A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
Leighl NB, Laurie SA, Chen XE, Ellis P, Shepherd FA, Knox JJ, Goss G, Burkes RL, Pond GR, Dick C, Yen Y, Zwiebel JA, Moore MJ. Leighl NB, et al. Among authors: laurie sa. J Thorac Oncol. 2009 Sep;4(9):1163-9. doi: 10.1097/JTO.0b013e3181a949b2. J Thorac Oncol. 2009. PMID: 19704337 Free PMC article. Clinical Trial.
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L. Goss GD, et al. Among authors: laurie sa. J Clin Oncol. 2010 Jan 1;28(1):49-55. doi: 10.1200/JCO.2009.22.9427. Epub 2009 Nov 16. J Clin Oncol. 2010. PMID: 19917841 Clinical Trial.
96 results